东曜药业获评“年度卓越生物医药企业”，生态创新价值持续获认可

Core Insights - Dongyao Pharmaceutical (1875.HK) has been awarded the "Annual Outstanding Biopharmaceutical Company" for its continuous innovation and stable growth in the biopharmaceutical sector [1][3]. Group 1: Award Significance - The "Annual Outstanding Biopharmaceutical Company" award focuses on R&D innovation, core product competitiveness, commercialization progress, and sustainable development potential, recognizing companies that create long-term value for the industry and investors [3]. - Dongyao Pharmaceutical's recognition reflects the market's deep acknowledgment of its unique development path and platform value amidst a focus on differentiated innovation and lean development in the biopharmaceutical industry [3][6]. Group 2: Competitive Advantages - The company has strategically focused on the ADC (Antibody-Drug Conjugate) technology, which has high market potential and significant barriers to entry, establishing a comprehensive platform that covers R&D, process development, clinical trials, regulatory approval, and commercial production [5][6]. - Dongyao Pharmaceutical is one of the few global CDMO service companies with an end-to-end service capability in the ADC industry, leveraging its technical expertise and large-scale production facilities to enhance its platform value [6][10]. Group 3: Financial Performance and Growth - The company has successfully commercialized its product, Puxintin® (Bevacizumab Injection), which has gained regulatory approval in Nigeria and Pakistan, contributing to stable cash flow and extending the product's lifecycle value [9][10]. - The CDMO business, particularly in the ADC sector, is experiencing significant growth, with 16 new projects added, including 14 ADC projects, and a total of 169 projects in progress, providing a high degree of revenue certainty for the future [10][12]. Group 4: Future Outlook - Dongyao Pharmaceutical's integrated platform model, centered on ADC technology, is expected to continue driving growth and creating value, positioning the company for sustained success in the capital markets [12].